An announcement from Lixte Biotechnology Holdings (LIXT) is now available.
In a significant corporate update, the Company has announced the appointment of Dr. Jan Schellens as the new Chief Medical Officer, effective from June 3, 2024. This move could signal strategic shifts and expertise enhancement, capturing the attention of investors tracking leadership changes in the stock market.
Find detailed analytics on LIXT stock on TipRanks’ Stock Analysis page.
